1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Roivant Plots ‘Streamlined’ Phase III As Ulcerative Colitis Data Raise Blockbuster Potential

 
• By Alaric DeArment

The company announced data from the Phase IIb TUSCANY-2 trial of RVT-3101, which is in a tight race with PRA023 from Prometheus, which Merck recently acquired for $10.8bn.

Ulcerative colitis endoscopic biopsy
Roivant announced Phase IIb results for RVT-3101 in ulcerative colitis • Source: Shutterstock

Data from Roivant Sciences Ltd.’s Phase IIb TUSCANY-2 trial of RVT-3101 set the anti-TL1A antibody up as a potential blockbuster treatment for ulcerative colitis amid what looks to become stiff competition with competitor PRA023 from Prometheus Biosciences, Inc, which Merck & Co., Inc. recently acquired.

Following previously disclosed induction phase data from TUSCANY-2, Roivant announced results on 22 June for all-comers as well as those...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Lyra Eyes US Filing For LYR-210 After Surprise ENLIGHTEN 2 Win

 
• By Sushmita Panda

In a turn of fortunes, Lyra Therapeutics has reported positive Phase III results for LYR-210 in chronic rhinosinusitis, boosting hopes for US approval. The company plans to submit an NDA and pursue further trials, but its cash position is precarious.

ASCO: Carvykti Data Raise Possibility Of Myeloma Cure

 
• By Alaric DeArment

J&J presented data at the American Society of Clinical Oncology meeting showing more than five-year disease- and therapy-free survival, but a myeloma working group will need to define what makes a cure.

Vigil’s Iluzanebart Disappoints In Rare Neurodegenerative Disease

 
• By Jessica Merrill

The Phase II TREM2 agonist is not part of Sanofi’s planned acquisition.

Merus Raises $300m After ASCO Success

 
• By Andrew McConaghie

The company is raising the money to fuel development of its head and neck cancer candidate, petosemtamab, on the back of promising early data. Some analysts are stopping short of declaring it the winner against a rival product from Bicara, however.

More from R&D

Degron Eyes Deals For Novel Molecular Glue Degrader Assets

 
• By Dexter Jie Yan

Pursuing first-in-class molecular glue degraders using undruggable targets could eventually help Degron Therapeutics land sizable asset-based deals, CEO Lily Zou tells Scrip.

Kymera STAT6 Data Set The Bar For ‘Dupixent-In-A-Pill’ Race

 
• By Jessica Merrill

Kymera will move KT-621 into Phase II trials later this year based on compelling data in healthy volunteers, validating the company’s protein-degradation platform.

ASCO: Zepzelca Tecentriq Combo A Lung Cancer Success For Jazz and Roche

 
• By Andrew McConaghie

Small-cell lung cancer treatment is rapidly evolving, but Jazz and Roche are set to create a new maintenance therapy setting with their Zepzelca plus Tecentriq combination.